Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.
Type 2 diabetes
bone geometry
bone mineral density
hypogonadism
testosterone
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
13 07 2021
13 07 2021
Historique:
received:
14
11
2020
pubmed:
19
3
2021
medline:
21
10
2021
entrez:
18
3
2021
Statut:
ppublish
Résumé
Male hypogonadism is associated with low bone mineral density (BMD) and increased fragility fracture risk. Patients with type 2 diabetes (T2D) have relatively higher BMD, but greater fracture risk. Evaluate the skeletal response to testosterone therapy in hypogonadal men with T2D compared with hypogonadal men without T2D. Single arm, open-label clinical trial (NCT01378299) involving 105 men (40-74 years old), with average morning testosterone <300 ng/dL. Subjects were injected intramuscularly with testosterone cypionate (200 mg) every 2 weeks for 18 months. Testosterone and estradiol were assessed by liquid chromatography/mass spectrometry; serum C-terminal telopeptide of type I collagen (CTX), osteocalcin and sclerostin by enzyme-linked immunosorbent assay; glycated hemoglobin (HbA1c) by high-performance liquid chromatography, areal BMD (aBMD) and body composition by dual-energy x-ray absorptiometry; tibial volumetric BMD (vBMD) and bone geometry by peripheral quantitative computed tomography. Among our population of hypogonadal men, 49 had T2D and 56 were non-T2D. After 18 months of testosterone therapy, there were no differences in circulating testosterone and estradiol between the groups. Hypogonadal men with T2D had increased osteocalcin, reflecting increased osteoblast activity, compared with non-T2D men (P < .01). T2D men increased lumbar spine aBMD (P < .05), total area at 38% tibia (P < .01) and periosteal and endosteal circumferences at the same site (P < .01 for both). T2D men had reduced tibial vBMD (P < .01), but preserved bone mineral content (P = .01). Changes in HbA1c or body composition were similar between the 2 groups. Testosterone therapy results in greater improvements in the skeletal health of hypogonadal men with T2D than their nondiabetic counterparts.
Identifiants
pubmed: 33735389
pii: 6178348
doi: 10.1210/clinem/dgab181
pmc: PMC8599870
doi:
Substances chimiques
Testosterone
3XMK78S47O
testosterone 17 beta-cypionate
M0XW1UBI14
Banques de données
ClinicalTrials.gov
['NCT01378299']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3058-e3068Subventions
Organisme : CSRD VA
ID : I01 CX001665
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD093047
Pays : United States
Informations de copyright
Published by Oxford University Press on behalf of the Endocrine Society 2021.
Références
Diabetes Care. 2016 Jan;39(1):82-91
pubmed: 26622051
J Bone Miner Res. 2020 Dec;35(12):2415-2422
pubmed: 32777114
Oxid Med Cell Longev. 2017;2017:4807046
pubmed: 28951766
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31858126
Front Endocrinol (Lausanne). 2020 May 15;11:277
pubmed: 32499757
Bone. 2017 Jun;99:14-19
pubmed: 28323146
Nat Rev Endocrinol. 2013 Dec;9(12):699-712
pubmed: 24042328
J Bone Miner Res. 2010 Feb;25(2):285-91
pubmed: 19594301
Cell. 2011 Mar 4;144(5):796-809
pubmed: 21333348
Diabetes. 1990 Apr;39(4):477-82
pubmed: 2180758
J Clin Endocrinol Metab. 2012 Sep;97(9):3240-50
pubmed: 22740707
J Endocr Soc. 2019 Jul 01;3(8):1617-1630
pubmed: 31403089
Calcif Tissue Int. 2017 Dec;101(6):602-611
pubmed: 28856390
J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3058-e3068
pubmed: 33735389
PLoS Genet. 2020 May 28;16(5):e1008586
pubmed: 32463816
Nat Rev Endocrinol. 2017 Apr;13(4):208-219
pubmed: 27658727
PLoS Genet. 2020 May 28;16(5):e1008361
pubmed: 32463812
Contemp Clin Trials Commun. 2021 Jan 20;21:100723
pubmed: 33718653
N Engl J Med. 2006 Nov 9;355(19):2048-50
pubmed: 17093260
J Clin Endocrinol Metab. 2010 Nov;95(11):5045-55
pubmed: 20719835
Best Pract Res Clin Rheumatol. 2009 Dec;23(6):741-53
pubmed: 19945686
J Bone Miner Res. 2011 Jan;26(1):27-34
pubmed: 20499362
J Clin Invest. 2000 Dec;106(12):1553-60
pubmed: 11120762
JAMA. 2006 Mar 15;295(11):1288-99
pubmed: 16537739
Front Endocrinol (Lausanne). 2021 Jan 18;11:607240
pubmed: 33537005
Int J Endocrinol. 2014;2014:690783
pubmed: 25140176
Ann Intern Med. 1987 Mar;106(3):354-61
pubmed: 3544993
JAMA Intern Med. 2017 Apr 1;177(4):471-479
pubmed: 28241231
Lancet Diabetes Endocrinol. 2016 Feb;4(2):159-73
pubmed: 26365605
J Clin Endocrinol Metab. 2001 Aug;86(8):3555-61
pubmed: 11502778
Eur J Endocrinol. 2015 Aug;173(2):167-74
pubmed: 26142101
Cell Metab. 2016 May 10;23(5):837-51
pubmed: 27133133
J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65
pubmed: 8954042
J Clin Endocrinol Metab. 2021 Apr 23;106(5):1362-1376
pubmed: 33537757
Clin Endocrinol (Oxf). 2001 Jun;54(6):739-50
pubmed: 11422108
J Clin Endocrinol Metab. 1999 Jun;84(6):1966-72
pubmed: 10372695
Int J Androl. 2011 Dec;34(6 Pt 1):528-40
pubmed: 20969599
Bone. 2000 Sep;27(3):351-7
pubmed: 10962345
Endocrinol Metab Clin North Am. 2014 Mar;43(1):233-43
pubmed: 24582100
J Clin Invest. 2013 Jun;123(6):2421-33
pubmed: 23728177
J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59
pubmed: 20525905
J Clin Endocrinol Metab. 2014 Jul;99(7):E1272-82
pubmed: 24670081
Proc Natl Acad Sci U S A. 1989 Feb;86(3):854-7
pubmed: 2915981
J Clin Endocrinol Metab. 2004 Nov;89(11):5462-8
pubmed: 15531498
Osteoporos Int. 2014 Jun;25(6):1697-708
pubmed: 24676844
Cell. 2001 Mar 9;104(5):719-30
pubmed: 11257226
Endocrine. 2019 Sep;65(3):692-706
pubmed: 31325085
Curr Opin Pharmacol. 2005 Dec;5(6):626-32
pubmed: 16185926